A trial for evaluation of effectiveness and safety for dose reduction DTP-IPV vaccination in adult

A trial for evaluation of effectiveness and safety for dose reduction DTP-IPV vaccination in adult - dose reduction vaccination of DTP-IPV in adult

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022793

Enrollment

Registered

2016-06-20

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy adult

Interventions

single dose vaccination: DTP-IPV vaccine 0.25 ml

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. work in the cooperating institute 2.Informed consent to participate in the study was given

Exclusion criteria

Exclusion criteria: 1. inoculated pertussis vaccine for adulthood 2. past history for pertussis infection 3. chronic kidney disease 4. immunodeficiency 5. using immunosuppresant or oral steroid 6. past history for anaphyraxis by vaccines 7. Judged inappropriate for this study by the physicians

Design outcomes

Primary

Measure	Time frame
pertussis antibody titer after vaccination	—

Countries

Japan

Contacts

Public ContactYoshihiko Morikawa

Tokyo Metropolitan Children's Medical Center Clinical Research Support Center

yoshihiko_morikwa@tmhp.jp042-300-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026